Johnson & Johnson (JNJ) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This report covers the fiscal third quarter ended September 28, 2025. Johnson & Johnson operates through two primary segments: Innovative Medicine and MedTech. The period was marked by significant strategic developments, including the completion of the Intra-Cellular Therapies acquisition (adding CAPLYTA to the portfolio) and a major announcement regarding the planned separation of the Orthopaedics business.
Key Financial Metrics
| Metric | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Sales to Customers | $23.99 Billion | $22.47 Billion | $69.63 Billion | $66.30 Billion |
| Net Earnings | $5.15 Billion | $2.69 Billion | $21.69 Billion | $10.64 Billion |
| Diluted EPS | $2.12 | $1.11 | $8.94 | $4.38 |
| Gross Margin | 69.6% | 69.0% | 68.0% | 69.3% |
| Operating Cash Flow (9M) | $17.22 Billion | |||
| Total Debt | $45.8 Billion (Current: $6.4B, Long-term: $39.4B) | |||
| Cash & Equivalents | $18.23 Billion |
Material Changes vs. Prior Period
- Revenue Growth: Worldwide sales increased 6.8% in Q3 and 5.0% for the nine months ended September 28, 2025. Operational growth was 5.4% (Q3) and 4.7% (9M), driven by acquisitions (CAPLYTA, Shockwave) and strong oncology sales, partially offset by STELARA biosimilar competition.
- Profitability Surge: Net earnings more than doubled in Q3 ($5.15B vs $2.69B) and the nine-month period ($21.69B vs $10.64B). This was primarily driven by a $7.0 billion reversal of previously accrued talc litigation reserves following the dismissal of the Red River bankruptcy case in March 2025.
- Segment Performance:
- Innovative Medicine: Sales up 6.8% (Q3). Oncology grew 21.3% (driven by DARZALEX, CARVYKTI, ERLEADA). Immunology declined 9.8% due to STELARA biosimilar erosion.
- MedTech: Sales up 6.8% (Q3). Cardiovascular grew 12.6% (driven by Abiomed and Shockwave). Orthopaedics grew 3.8%.
- Acquisitions: The $14.5 billion Intra-Cellular Therapies acquisition closed in April 2025, contributing to Neuroscience sales. The Shockwave acquisition (closed May 2024) continues to drive MedTech growth.
Guidance, Outlook, and Risks
- Strategic Separation: On October 14, 2025, the Company announced its intention to separate its Orthopaedics business, targeting completion within 18 to 24 months.
- Restructuring: Ongoing restructuring programs in the Surgery and Orthopaedics franchises are expected to cost between $0.9B-$1.0B and $0.7B-$0.8B respectively, with substantial completion expected by end of fiscal 2026 and 2025.
- Tax Rate Impact: The effective tax rate for the nine months was 21.5% (vs 16.9% in 2024), impacted by the U.S. "One Big Beautiful Bill Act" (OBBBA) enacted in July 2025, which increased the statutory tax rate on foreign earnings and included a one-time remeasurement cost of approximately $1.0 billion.
- Legal Contingencies:
- Talc: Following the bankruptcy dismissal, the Company returned to the tort system. The remaining reserve is approximately $3.8 billion. Bellwether trials are scheduled for late 2025 and early 2026.
- Opioids: Approximately 80% of the $5.0 billion state settlement has been paid. Remaining litigation includes ~23 state cases and 285 MDL cases.
- Patent Litigation: Ongoing challenges for key products including XARELTO, INVEGA SUSTENNA, and ERLEADA.
Investor Verification Checklist
- Talc Reserve Adequacy: Verify the sufficiency of the remaining $3.8 billion talc reserve given the return to the tort system and upcoming bellwether trials.
- Orthopaedics Separation: Monitor the timeline and structure of the planned Orthopaedics spin-off and its impact on future segment reporting and debt allocation.
- STELARA Decline: Assess the long-term revenue impact of STELARA biosimilar launches in the U.S. and Europe, which offset significant growth in other Immunology and Oncology products.
- Tax Rate Normalization: Evaluate the sustainability of the effective tax rate post-OBBBA implementation and potential impacts of global Pillar Two tax rules.
- Acquisition Integration: Review the integration progress and revenue contribution of the Intra-Cellular Therapies (CAPLYTA) and Shockwave acquisitions.